April 27 (Reuters) - Align Technology Inc ::Align Technology Inc - qtrly net revenues $310.3 million versus $238.7 million.Align Technology Inc - qtrly earnings per share $0.85.Align - sees q2 invisalign case shipments in range of 221 thousand to 224 thousand.Align - sees q2 net revenues in range of $340 million to $345 million.Align - sees q2 diluted eps in range of $0.71 to $0.74.Q1 earnings per share view $0.67, revenue view $297.5 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.71, revenue view $324.7 million -- Thomson Reuters I/B/E/S.
April 27 (Reuters) - Biosynex SA ::FY operating profit of 0.8 million euros ($870,000.00) versus loss of 0.3 million euros year ago.FY net loss of 0.1 million euros versus loss of 0.3 million euros year ago.
April 27 (Reuters) - Biosino Bio-Technology and Science Incorporation <8247.HK>::Biosino Suzhou and SZMI entered into technology transfer agreement.Deal at consideration of rmb15 million.Biosino Suzhou to buy from SZMI, design and manufacturing technology, equipment & related patents for flow cytometer.Biosino Suzhou and IBP entered into patent transfer agreement under which ibp agreed to sell patents.Under patent transfer agreement, Biosino Suzhou agreed to prepay rmb3 million to IBP to fund research, development of patents.
April 27 (Reuters) - Biotage AB :Q1 Net sales amounted to 185.2 MSEK (158.9), an increase by 16.6 percent compared to the corresponding quarter last year.Q1 Operating profit increased by 48 percent to 34.9 MSEK (23.6).
April 27 (Reuters) - Rti Surgical Inc :Rti surgical® announces 2017 first quarter results.Q1 revenue $69.9 million.Sees fy 2017 adjusted earnings per share $0.05 to $0.10 excluding items.Sees fy 2017 earnings per share $0.01 to $0.06.Q1 loss per share $0.05.Fy2017 earnings per share view $0.08, revenue view $280.2 million -- Thomson Reuters I/B/E/S.
April 27 (Reuters) - Meridian Bioscience Inc :Meridian bioscience reports second quarter 2017 operating results, declares regular cash dividend, and reaffirms fiscal 2017 guidance.Sees fy 2017 earnings per share $0.64 to $0.69.Q2 earnings per share $0.22.Sees fy 2017 revenue $193 million to $199 million.Fy2017 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Q2 net revenues $54.1 million, up 6%.Q2 earnings per share view $0.19, revenue view $51.2 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $194.6 million -- Thomson Reuters I/B/E/S.Meridian bioscience inc - revenue and earnings guidance does not include impact of any acquisitions company may complete during fiscal 2017.
April 27 (Reuters) - Zimmer Biomet Holdings Inc :Zimmer biomet reports first quarter 2017 financial results.Zimmer biomet reports first quarter 2017 financial results.Q1 adjusted earnings per share $2.13.Q1 sales rose 3.8 percent to $1.98 billion.Sees fy 2017 earnings per share $4.68 to $4.88.Q1 earnings per share $1.47.Sees fy 2017 revenue up 2 to 3 percent.Now estimates full-year, constant currency revenue to increase between 3.2% and 4.2% compared to prior year,.Now expects foreign currency translation to decrease revenue for full year by approximately 1.2%.Sees full-year 2017 revenue to be in a range of $7.835 billion to $7.915 billion.Fy2017 earnings per share view $8.60, revenue view $7.89 billion -- Thomson Reuters I/B/E/S.Q1 earnings per share view $2.11, revenue view $1.96 billion -- Thomson Reuters I/B/E/S.
April 27 (Reuters) - West Pharmaceutical Services Inc :West announces first-quarter 2017 results.Q1 sales rose 7.1 percent to $387.7 million.Sees fy 2017 earnings per share $2.66 to $2.78.Q1 earnings per share $0.81.Sees fy 2017 sales $1.585 billion to $1.61 billion.West pharmaceutical services inc - reaffirming full-year 2017 sales and raising reported-diluted eps guidance.Fy2017 revenue view $1.60 billion -- Thomson Reuters I/B/E/S.Q1 revenue view $380.4 million -- Thomson Reuters I/B/E/S.
April 27 (Reuters) - Bio Gate AG ::For 2017 further growth and positive group result expected.2016 sales up by more than 20 percent to 3.746 million euros ($4.08 million) (previous year: 3.081 million euros).FY EBITDA improved by 521,000 euros to 301,000 euros (previous year: loss 220,000 euros).FY EBIT rose by 0.569 million euros in the financial year 2016 to 19,000 euros (previous year: -0.550 million euros).After strong increase in sales in 2016, Bio-Gate expects also for 2017 with a clear growth.
April 27 (Reuters) - Amplifon SpA ::Q1 net profit EUR 12.8 million ($13.95 million) versus EUR 8.6 million year ago.Q1 revenue EUR 296.1 million versus EUR 254.5 million year ago.For the rest of 2017, the company expects the favorable trend in revenues to continue, outpacing the market.For the rest of 2017, the company also expects profitability to improve with respect to the prior year.The company reiterates its complete confidence in the ability to implement and execute the strategic guidelines announced previously, as well as achieve its medium-long-term targets.